Neurology · Clinical trials
Huntington's Disease Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About huntington's disease — and why its trials are hard
Huntington's disease (HD) is a fatal, autosomal-dominant neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the HTT gene, producing a toxic mutant huntingtin protein. It manifests with progressive chorea and other movement abnormalities, cognitive decline, and psychiatric symptoms, typically beginning in mid-adulthood and progressing over 15-20 years. Critically, there is no disease-modifying or neuroprotective therapy approved; all current treatments are symptomatic. Chorea is managed with VMAT2 inhibitors: tetrabenazine (the first FDA-approved HD drug, 2008), the deuterated analogue deutetrabenazine, and valbenazine, approved in 2023 for HD chorea based on the KINECT-HD trial. Psychiatric and other symptoms are treated with antipsychotics, antidepressants, and supportive care. The disease-modification landscape is marked by prominent failures: the huntingtin-lowering antisense oligonucleotide tominersen had its GENERATION-HD1 phase 3 dosing halted after an unfavourable benefit-risk assessment, and the sigma-1/dopamine-modulating agent pridopidine failed to meet its primary endpoint in the PROOF-HD trial. Genetic counselling and predictive testing are central to management. Endpoints commonly use the Unified Huntington's Disease Rating Scale (UHDRS), including its Total Motor Score and Total Maximal Chorea score.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Tetrabenazine (Xenazine) | 2008 | Chorea associated with HD (first FDA-approved drug for any HD feature) | TETRA-HD | Change in UHDRS Total Maximal Chorea (TMC) score | Significant reduction in chorea vs placebo (~-3 to -5 point TMC improvement); short half-life requires frequent dosing |
| Deutetrabenazine (Austedo) | 2017 | Chorea associated with HD (deuterated VMAT2 inhibitor with longer half-life) | First-HD | Change in UHDRS Total Maximal Chorea score | TMC improved ~2.5 points more than placebo; smoother pharmacokinetics/tolerability than tetrabenazine |
| Valbenazine (Ingrezza) | 2023 | Chorea associated with HD (once-daily VMAT2 inhibitor) | KINECT-HD | Change in UHDRS Total Maximal Chorea score | ~3.2-point placebo-adjusted reduction in TMC over 12 weeks; once-daily dosing |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in huntington's disease development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Tominersen (HTT-lowering antisense oligonucleotide) — GENERATION-HD1 (phase 3) | Dosing halted in 2021 after an independent review found unfavourable benefit-risk; higher-dose arm trended worse than placebo | Possible excess CSF/dosing-related harm and no clinical benefit at tested regimens; a lower-dose/younger-patient study (GENERATION-HD2) was later pursued |
| Pridopidine (sigma-1 receptor agonist) — PROOF-HD (phase 3) | Failed to meet the primary endpoint (Total Functional Capacity) and key secondary endpoints | No significant functional benefit; earlier PRIDE-HD had also failed its motor endpoint |
| Coenzyme Q10 / creatine (neuroprotection candidates) — 2CARE (CoQ10); CREST-E (creatine) | Both large phase 3 trials stopped early for futility with no slowing of decline | Antioxidant/energetic hypotheses did not translate into disease modification |
Choosing the right endpoint
Primary endpoints that matter in huntington's disease trials
- UHDRS Total Maximal Chorea (TMC) score — Primary endpoint for VMAT2-inhibitor chorea trials (TETRA-HD, First-HD, KINECT-HD)
- UHDRS Total Motor Score (TMS) — Broad motor assessment used across HD studies
- Total Functional Capacity (TFC) — Measures independence/daily function; primary endpoint in disease-modification trials such as PROOF-HD
- Composite UHDRS (cUHDRS) — Multidomain endpoint combining motor, cognitive, and functional measures, used in tominersen trials
- Neurofilament light chain (NfL) — Fluid biomarker of neurodegeneration; used as a pharmacodynamic/target-engagement readout in ASO trials
How iNGENū runs huntington's disease trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Huntington's Disease clinical trials — FAQs
Is there a treatment that slows Huntington's disease?
What happened with the huntingtin-lowering drug tominersen?
How is chorea in Huntington's disease treated?
Ready to discuss your huntington's disease trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal